Effect of Hepatic Impairment on the Pharmacokinetics and Safety of VIR-2218 and VIR-3434

Recruiting

Phase 1

VIR-2218 & VIR-3434Effect of Hepatic Impairment on the Pharmacokinetics and Safety of VIR-2218 and VIR-3434

Sponsor:

Vir Biotechnology, Inc.

Code:

NCT05484206

Conditions

Hepatic Impairment

Cirrhosis

Eligibility Criteria

Sex: All

Age: 18 - 70

Healthy Volunteers: Accepted

Interventions

VIR-2218

VIR-3434

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-06-16. This information was provided to ClinicalTrials.gov by Vir Biotechnology, Inc. on 2024-05-03.